Working Hours

By Appointment

Scrambler Therapy

Frequently Asked Questions

Want to know more about Scrambler Therapy?

Check out our FAQ below.

Frequently Asked Questions

The technology known in clinical publications as Scrambler TherapyTM was developed by Professor Giuseppe Marineo in Rome, Italy. His research of chronic pain began over 24 years ago.

Over 3,500 patients have been treated in Europe,
and over 600 patients in the US.

Neuropathic and oncologic pain. Severe chronic neuropathic pain non-responsive to pharmaceutical treatment, traditional TENS, or implanted devices.

Neuropathic and Oncologic Pain: The initial treatment protocol consists of 10-12 consecutive treatments of 30 to 45 minutes once a day (5 days a week for 2 weeks). Additional “booster treatments” maybe needed.

Yes. In most cases, after the initial treatment protocol patients experience reduced or no pain. However, it is most important that the chronic pain is first properly diagnosed as neuropathic or oncologic and not musculoskeletal pain.

The average recorded “no pain” period is 1 to 3 months, with 1 year being the longest interval without “booster treatments.” Patients who have had chronic pain for an extended period of time will most likely require “booster treatments”.

Unlike traditional TENS devices and some spinal cord stimulators, Calmare® Pain Therapy Treatment is effective in treating visceral oncologic pain and CIPN (chemotherapy-induced peripheral neuropathy). The type of cancer or the stage of cancer may not allow for lengthy “no pain” periods. Frequency of “booster treatments” will depend on the specific needs of individual patients.

Acute pain and chronic pain that is diagnosed as musculoskeletal pain and not neuropathic pain. Additionally, “non receptive” refers to patients who do not experience pain relief or diminished pain after a treatment (or several treatments) or not possible to localize a specific pain site. Also, pain caused from “active inflammation” that continuously damages the nerve fibers (connective tissue diseases, musculoskeletal pain devoid of neuropathic component and arthritis).

On July 1, 2011 the AMA announced CPT 0278T (effective Jan. 1, 2012) to report Scrambler TherapyTM. This does not guarantee that insurers will or will not cover Calmare®. At this time health converage for Calmare® is determined on an individual basis. Some insurers have convered Calmare® treatments.

Question Not Answered?

Ask In The Form

410.870.5482